Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.651 |
---|---|
High | 0.67 |
Low | 0.64 |
Bid | 0.6403 |
Offer | 0.68 |
Previous close | 0.66 |
Average volume | 120.59k |
---|---|
Shares outstanding | 4.33m |
Free float | 4.00m |
P/E (TTM) | -- |
Market cap | 2.86m USD |
EPS (TTM) | -107.62 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:10 GMT.
More ▼
- Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model
- Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability
- Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement
- Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually
- Scorpius Holdings Announces Partnership with U.S. Biotech Company
- Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats
- Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities
- Scorpius Holdings Commends the U.S. House of Representatives’ Passage of the BIOSECURE Act
- Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA
- Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow
More ▼